Pilot Study for Cyproheptadine in Hospitalized Patient for COVID-19
Status:
Not yet recruiting
Trial end date:
2022-01-31
Target enrollment:
Participant gender:
Summary
This is a Pilot study for evaluating the feasibility, security and efficacy of the use of
Cypropheptadine, an antihistaminic and antiserotonin drug, as an adjunct of the standardized
treatment in a population of patient who are hospitalized and requiring oxygen therapy for
COVID-19.